Motor issues like low muscle tone, poor coordination, and physical fatigue are common in autism—but often go unaddressed by current treatments. These symptoms are more than physical. They affect how people move through the world, interact with others, and gain independence.
RT2234 was developed to address this overlooked need. By targeting neuroinflammation, oxidative stress, and neuromuscular signaling, it aims to improve physical control, stamina, and confidence—without sedation or stimulant side effects
RT2234 is a novel therapeutic agent designed to modulate the Cholinergic Anti-Inflammatory Pathway (CAP). This innovative compound desensitizes specific receptors without activating them, providing a targeted approach to reducing neuroinflammation while offering cytoprotective and neuroprotective benefits.
RT2234 is designed to restore physical strength and coordination in individuals with autism, supporting greater independence and engagement in daily life.
The biological challenges RT2234 addresses—like muscle fatigue, mitochondrial dysfunction, and chronic inflammation—are not limited to autism. They are also central to a range of conditions that affect physical function across the lifespan.
RT2234’s mechanism makes it a strong candidate for treating sarcopenia, frailty, and other forms of neuromuscular decline, especially in aging populations. By improving tone, energy production, and recovery, it may offer a new path forward in conditions where strength and stamina are often overlooked.
